Patents by Inventor David Bettoun

David Bettoun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10954194
    Abstract: The invention relates to a method of treating a subject who has cancer or a non-malignant tumor, the method comprising administering a therapeutically effective amount of a 18-20 member bi-polycyclic compound to the subject.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: March 23, 2021
    Assignees: Haro Pharmaceuticals Inc., The Royal Institution for the Advancement of Learning/ McGill University, Universite De Montreal
    Inventors: David Bettoun, Eduardo Martinez, James Gleason, Sylvie Mader, Shuo Xing
  • Publication number: 20200377951
    Abstract: The present disclosure is based, at least in part, on providing a set of markers, also referred to herein as FXN-sensitive genomic markers (or FSGMs), the respective expression levels of which are positively or negatively correlated to frataxin (FXN) levels in a cell. Therefore, these FSGMs can be used to determine, evaluate, and/or monitor the effectiveness of FXN replacement therapy in a subject.
    Type: Application
    Filed: April 30, 2020
    Publication date: December 3, 2020
    Inventor: Joan David Bettoun
  • Patent number: 10752591
    Abstract: The invention relates to a method of inhibiting loss of muscle mass or muscle function in a subject in need thereof, or a method of treating miofibers ex vivo, the method comprising administering a therapeutically effective amount of a 18-20 member bi-polycyclic compound to the subject or to the miofibers.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: August 25, 2020
    Assignees: Haro Pharmaceuticals Inc., The Royal Institution for the Advancement of Learning/McGill University, Universite De Montreal
    Inventors: David Bettoun, Eduardo Martinez, James Gleason, Sylvie Mader, Shuo Xing
  • Publication number: 20190389806
    Abstract: The invention relates to a method of inhibiting loss of muscle mass or muscle function in a subject in need thereof, or a method of treating miofibers ex vivo, the method comprising administering a therapeutically effective amount of a 18-20 member bi-polycyclic compound to the subject or to the miofibers.
    Type: Application
    Filed: July 3, 2019
    Publication date: December 26, 2019
    Inventors: David Bettoun, Eduardo Martinez, James Gleason, Sylvie Mader, Shuo Xing
  • Publication number: 20190389805
    Abstract: The invention relates to a method of treating a subject who has cancer or a non-malignant tumor, the method comprising administering a therapeutically effective amount of a 18-20 member bi-polycyclic compound to the subject.
    Type: Application
    Filed: July 3, 2019
    Publication date: December 26, 2019
    Inventors: David Bettoun, Eduardo Martinez, James Gleason, Sylvie Mader, Shuo Xing
  • Patent number: 10377715
    Abstract: The invention relates to 18-20 member bi-polycyclic compounds, methods of making these compounds, and methods of using them in treating hyperproliferative disorders (e.g., cancer) and non-malignant tumors; promoting muscle formation; inhibiting muscle degeneration or the loss of muscle mass or muscle function; and myofibers ex vivo.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: August 13, 2019
    Assignees: Haro Pharmaceuticals Inc., The Royal Institution for the Advancement of Learning/ McGill University, Universite De Montreal
    Inventors: David Bettoun, Eduardo Martinez, James Gleason, Sylvie Mader, Shuo Xing
  • Publication number: 20180362467
    Abstract: The invention relates to 18-20 member bi-polycyclic compounds, methods of making these compounds, and methods of using them in treating hyperproliferative disorders (e.g., cancer) and non-malignant tumors; promoting muscle formation; inhibiting muscle degeneration or the loss of muscle mass or muscle function; and myofibers ex vivo.
    Type: Application
    Filed: December 6, 2017
    Publication date: December 20, 2018
    Inventors: David Bettoun, Eduardo Martinez, James Gleason, Sylvie Mader, Shuo Xing
  • Publication number: 20170114019
    Abstract: The invention relates to 18-20 member bi-polycyclic compounds, methods of making these compounds, and methods of using them in treating hyperproliferative disorders (e.g., cancer) and non-malignant tumors; promoting muscle formation; inhibiting muscle degeneration or the loss of muscle mass or muscle function; and myofibers ex vivo.
    Type: Application
    Filed: June 4, 2015
    Publication date: April 27, 2017
    Inventors: David Bettoun, Eduardo Martinez, James Gleason, Sylvie Mader, Shuo Xing
  • Publication number: 20090117046
    Abstract: The invention discloses a knockout mouse that is homozygous for a RUNX3 null allele, as a novel model for chronic inflammatory disease. The present invention provides methods of diagnosing and assessing predisposition to chronic inflammatory diseases. The present invention further provides methods for testing agents for effectiveness in treating and/or preventing diseases associated with chronic inflammatory or autoimmune conditions.
    Type: Application
    Filed: January 12, 2009
    Publication date: May 7, 2009
    Inventors: Yoram GRONER, David Bettoun
  • Publication number: 20060264393
    Abstract: The invention discloses a knockout mouse that is homozygous for a RUNX3 null allele, as a novel model for chronic inflammatory disease. The present invention provides methods for treating T cell-related inflammatory conditions by cell therapy, gene therapy or antisense for up regulating or down regulating RUNX3. The invention further relates to methods of diagnosing and assessing predisposition to chronic inflammatory diseases. The present invention further provides methods for testing agents for effectiveness in treating and/or preventing diseases associated with chronic inflammatory or autoimmune conditions.
    Type: Application
    Filed: December 30, 2003
    Publication date: November 23, 2006
    Inventors: Yoram Groner, David Bettoun